

Andrew has worked in the Boston area pharmaceutical industry since 1996 where he has held leadership positions in start-up to midsize biopharmaceutical companies, including EPIX Pharmaceuticals and Flatley Discovery Lab. He has over 25 years experience in research and development, and contributed to the discovery and development of molecularly targeted MRI contrast agents for diagnosis of cardiovascular disease, thrombosis, and fibrosis, G-Protein coupled receptor agonists and antagonists for treatment of inflammatory diseases, and modulators of CFTR, the protein defective in cystic fibrosis. He received his Ph.D. in chemistry from MIT, and is a board certified toxicologist.